Correction: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2025) Published: 2026 Correction to: Aging Clinical and Experimental Research (2025) 37:279 https://doi.org/10.1007/s40520-025-03119-z In this article, the P1576, P1577 and P1578 abstract was missing and should have read P1576 BONE TURNOVER IN POSTMENOPAUSAL WOMEN: EVALUATING THE IMPACT OF ESTETROL (E4) FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 3 TRIAL J. Douxfils1, A. Black2, M. Taziaux3, U. Gaspard4, E. Kapoor5, R. A. Lobo6, W. H. Utian7, J.-M. Foidart4 1University of Namur, Namur, Belgium, 2University of Ottawa, Ottawa, Canada, 3Estetra SRL, a wholly owned company of Gedeon Richter PLC, Liège, Belgium, 4University of Liège, Liège, Belgium, 5Mayo Clinic, Rochester, Minnesota, United States, 6Department of Obstetrics and Gynecology, Columbia University, New York City, United States, 7Case Western Reserve University School of Medicine, Cleveland, United States Objective: Estetrol (E4) is a naturally occuring estrogen effective in reducing menopausal vasomotor symptoms (VMS) with minimal impact on hemostasis and potential metabolic benefits. Estrogen therapy alleviates moderate to severe VMS and helps counteract menopause-related bone turnover acceleration. A Phase 2 study previously showed E4 15 mg reduces bone turnover biomarkers, suggesting a beneficial effect. This Phase 3 study assesses E4 impact on these markers after 12 and 52 weeks in postmenopausal (PM) women. Design: E4Comfort II (NCT04090957) was a double-blind, placebo-controlled, multicenter trial conducted at 122 US and Canadian sites to evaluate E4 efficacy and safety for treating moderate-to-severe VMS in PM women aged 40–65. A total of 579 participants received E4 15 mg (n = 192), E4 20 mg (n = 193), or placebo (n = 194) once daily for 52 weeks. Blood samples were collected at baseline, week 12 (W12), and week 52 (W52) for CTX-1, P1NP, calcium, and vitamin D analysis. Mixed Model Repeated Measures was used for statistical comparisons (p < 0.05 significant). Results: CTX-1 significantly decreased with E4 vs. placebo at W12 and W52 (all p < 0.0001). P1NP levels also declined significantly at W12 (p = 0.0220 for 15 mg; p < 0.0001 for 20 mg) and W52 (all p < 0.0001). Calcium decreased significantly vs. placebo at W12 (p = 0.0004 for 15 mg; p < 0.0001 for 20 mg) and at W52 for 20 mg (p < 0.0001). No significant vitamin D changes were observed. Conclusion: E4 reduces CTX-1 and P1NP, indicating lower bone turnover, suggesting a beneficial role in maintaining bone strength and potentially preventing osteoporosis in postmenopausal women. Table 1Change from Baseline to Week 12 and Week 52 for Bone Turnover BiomarkersBone markersE4 15 mg (N = 192)E4 20 mg (N = 193)Placebo (N = 194)LS mean CFB (95% CI)p-value(vs. placebo)LS mean CFB (95% CI)p-value(vs. placebo)LS mean CFB (95% CI) CTX-1 (µg/L) W12-0.15 (-0.18, -0.12) < 0.0001 -0.15 (-0.19, -0.12) < 0.0001 -0.02 (-0.05, 0.01)W52-0.19 (-0.22, -0.15) < 0.0001 -0.16 (-0.20, -0.12) < 0.0001 -0.02 (-0.05, 0.02) PINP (µg/L) W12-8.45 (-11.99, -4.91) 0.0220 -13.84 (-17.40, -10.27) < 0.0001 -2.22 (-5.71, 1.26)W52-16.08 (-20.57, -11.59) < 0.0001 -13.83 (-18.63, -9.03) < 0.0001 -0.15 (-4.34, 4.04) Calcium (mmol/L) W12-0.04 (-0.06, -0.03) 0.0004 -0.08 (-0.09, -0.06) < 0.0001 0.00 (-0.02, 0.02)W52-0.07 (-0.09, -0.04)0.0898-0.11 (-0.13, -0.08) < 0.0001 -0.04 (-0.06, -0.02) Vitamin D (nmol/L) W122.37 (-1.92, 6.66)0.7531-2.19 (-6.46, 2.07)0.55480.51 (-3.66, 4.67)W5213.89 (8.44, 19.33)0.11705.52 (-0.29, 11.34)0.8857.07 (1.97, 12.17)LS: Least Squares Table 1Change from Baseline to Week 12 and Week 52 for Bone Turnover BiomarkersBone markersE4 15 mg (N = 192)E4 20 mg (N = 193)Placebo (N = 194)LS mean CFB (95% CI)p-value(vs. placebo)LS mean CFB (95% CI)p-value(vs. placebo)LS mean CFB (95% CI) CTX-1 (µg/L) W12-0.15 (-0.18, -0.12) < 0.0001 -0.15 (-0.19, -0.12) < 0.0001 -0.02 (-0.05, 0.01)W52-0.19 (-0.22, -0.15) < 0.0001 -0.16 (-0.20, -0.12) < 0.0001 -0.02 (-0.05, 0.02) PINP (µg/L) W12-8.45 (-11.99, -4.91) 0.0220 -13.84 (-17.40, -10.27) < 0.0001 -2.22 (-5.71, 1.26)W52-16.08 (-20.57, -11.59) < 0.0001 -13.83 (-18.63, -9.03) < 0.0001 -0.15 (-4.34, 4.04) Calcium (mmol/L) W12-0.04 (-0.06, -0.03) 0.0004 -0.08 (-0.09, -0.06) < 0.0001 0.00 (-0.02, 0.02)W52-0.07 (-0.09, -0.04)0.0898-0.11 (-0.13, -0.08) < 0.0001 -0.04 (-0.06, -0.02) Vitamin D (nmol/L) W122.37 (-1.92, 6.66)0.7531-2.19 (-6.46, 2.07)0.55480.51 (-3.66, 4.67)W5213.89 (8.44, 19.33)0.11705.52 (-0.29, 11.34)0.8857.07 (1.97, 12.17)LS: Least Squares Change from Baseline to Week 12 and Week 52 for Bone Turnover Biomarkers LS: Least Squares Source of funding: The study was funded by Estetra SRL, Belgium, a wholly owned company of Gedeon Richter PLC, Liège. P1577 EARLY CLINICAL DEVELOPMENT OF COMBINATION DRUG CANDIDATE RJX-01 FOR THE TREATMENT OF SARCOPENIA J. Aerssens1, E. Mercken1, L. Meuleners1, L. Haazen1, D. Kanters1, S. Corveleyn1, D. Bwirire1, A. Beliën1 1Rejuvenate Biomed nv, Diepenbeek, Belgium Objective: The novel combination drug candidate RJx-01 was shown to exert beneficial synergistic effects on muscle strength and physical performance in preclinical studies. It was proposed to evaluate the potential of RJx-01 in human clinical trials as a therapeutic intervention for sarcopenia. Material and Methods: A Phase 1 study was conducted in 42 healthy men (65–75 years old) during and after 2 weeks of muscle inactivity (immobilization by leg casting) to assess the tolerability, safety and effect on muscle strength of 6 weeks daily treatment with RJx-01. Results: In healthy elderly volunteers, 6 weeks of RJx-01 treatment was safe and well tolerated. Compared to placebo-treated subjects (n = 21), RJx-01 treatment (n = 21) induced faster and better recovery of muscle strength in the leg after 2 weeks of immobilization (isometric analysis). During isokinetic measurements, RJx-01 treatment showed significantly improved muscle function (rate of velocity development) and resistance to muscle fatigue in the casted leg. We then designed a Phase 2 study to evaluate the safety and effects of longer term (6 months) treatment with RJx-01 on muscle integrity in elderly COPD patients. Unplanned hospitalization for severe acute exacerbation is a major event for COPD patients and the associated disability can lead to significant functional decline. The skeletal muscle dysfunction seen in COPD is part of the spectrum seen in sarcopenia. We hypothesize that RJx-01 treatment may have beneficial effects on functional performance of these patients. Conclusion: Following a Phase 1 study showing initial evidence of safety and efficacy of RJx-01 in an acute sarcopenia model, a Phase 2 program was initiated. A first study will assess the longer-term response to RJx-01 treatment in COPD patients at risk of developing chronic sarcopenia. Additional Phase 2 studies in other patient populations where sarcopenia has a significant impact on disease burden are being considered. Disclosures: All co-authors were employed or funded by Rejuvenate Biomed. P1578 ONLINE ACCESS TO NOGG GUIDELINES IN 2024; INTERACTION WITH FRAX AND INTERNATIONAL VISIBILITY C. Gregson1,2, D. J. Armstrong3, J. Bowden4, C. Cooper5,6, J. Edwards7,8, N. J. L. Gittoes9, N. C. Harvey5, J. A. Kanis10, S. Leyland11, R. Low12, K. Moss13, J. Parker4, Z. Paskins14, K. Poole15, D. M. Reid16, M. Stone17, J. Tomson11, N. Vine4, J. Compston18, E. V. McCloskey19 1Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom, 2Royal United Hospital NHS Foundation Trust, Bath, United Kingdom, 3Western Health and Social Care Trust (NI), and Nutrition Innovation Centre for Food and Health, Ulster University, Ulster, United Kingdom, 4National Osteoporosis Guideline Group, United Kingdom, 5MRC Lifecourse Epidemiology Centre, University of Southampton, UK; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 6NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom, 7Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, United Kingdom, 8Wolstanton Medical Centre, Newcastle under Lyme, United Kingdom, 9Queen Elizabeth Hospital, University Hospitals Birmingham & University of Birmingham, Centre for Endocrinology, Diabetes and Metabolism, Birmingham, United Kingdom, 10Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom, 11Royal Osteoporosis Society, United Kingdom, 12Marcham Road Health Centre, Abingdon and Specialty Doctor in Metabolic Bone Disease, Nuffield Orthopaedic Centre, Oxford, United Kingdom, 13Dr. Katie Moss, St George’s University Hospital, London, United Kingdom, 14School of Medicine, Keele University, Keele. Haywood Academic Rheumatology Centre, Haywood Hospital, Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, United Kingdom, 15Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 16Prof. David M Reid, University of Aberdeen, Aberdeen, United Kingdom, 17University Hospital Llandough, Cardiff, United Kingdom, 18University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom, 19Versus Arthritis Centre for Integrated research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, United Kingdom The UK National Osteoporosis Guideline Group published updated guidance for the Prevention and Treatment of Osteoporosis in 2021. The guideline aims to provide clinically appropriate recommendations by integrating available evidence on clinical efficacy, effectiveness and safety. It is intended for use by all healthcare professionals involved in the prevention and treatment of osteoporosis and fragility fractures, including primary care practitioners, allied health professionals and relevant specialists in secondary care. The guideline is provided in full on the NOGG website (https://www.nogg.org.uk/) which permits audit of online access to the website by users. We aimed to audit website views and users over the period 1st January-31st December 2024. In 2024, the NOGG website had a total of 936,217 views, a single view being a page on the website being seen by a visitor. Of these views, the majority (625,498, 66.8%) were views arising after calculated FRAX 10-year probabilities, with the user being sent directly from the UK FRAX website to the NOGG Guideline website. Most of these FRAX-based views (62.0%) were calculations conducted without femoral neck BMD input, suggesting FRAX was being used to determine the need for DXA assessment and/or treatment. Of the other pages viewed, the NOGG home page was the most viewed (70,426 times) followed by the Full Guideline page (46,857 views). Views showed a classical 5-day working week pattern, with an average of 3,601 views per working day (Figure-1). Over the year, a total of 781,643 users accessed the website; as expected, most users were based in the UK (685,427, 87.7%), but users were also documented in at least 57 other countries, with the top 3 countries being Ireland (2.3% of users), Brazil (1.7%) and the USA (1.3%). This audit demonstrates very active use of the NOGG website. The use is largely driven by the direct link between the FRAX UK tool and the NOGG website, a facility that only exists for a small number of countries currently but can easily be set-up for other countries. The NOGG website and guideline has very good international visibility and engagement; it provides a suitable guideline template that other countries could contextually adapt. Figure 1 Views by page path and screen class over time. Total views in 2024 = 936,217